INTRODUCTION
USP (an acronym for the United States Pharmacopeial Convention, Inc., which was incorporated in 1900 in the District of Columbia) was formed in 1820 by practitioners who wished to standardize the recipes (process standards) used to prepare pharmaceuticals and give them unique, clear, and useful names. With the rise in modern pharmaceutical manufacturing, this role has changed so that USP now provides product standards for therapeutic ingredients and dosage forms to assure their strength, quality, and purity. These ingredients and dosage forms are termed articles, as in articles of commerce, both in the United States Pharmacopeia and the National Formulary (USP -NF) and also in the United States Federal Food, Drug, and Cosmetic Act (FFDCA). Therapeutic articles include biologics, chemically synthesized drugs, excipients, dietary supplements, and some devices. Standards are available for more than 4000 ingredient and dosage form monographs in USP -NF . These standards include the article ' s defi nition, description, brief packaging, storage, and labeling statements, and a specifi cation (ie, tests, procedures, and acceptance criteria). A monograph is intended to be unambiguous so that any individual with the requisite training and equipment can successfully conduct the required tests. If an article meets the stipulations of the monograph when tested, then its identity, under its name, is established. USP -NF still contains a small number of recipes for use by compounding practitioners, refl ective of the intent of the early Pharmacopeia.
As a nonprofi t 501 (c)(3) corporation, USP differs from most pharmacopeias of the world insofar as the latter typically function in close association with one or more governments and may be governmental or quasi-governmental bodies.
The governing bodies of USP (Convention and Board of Trustees) as well as its standards-setting body (Council of Experts) are composed entirely of volunteers. Their mission is to promote … the public health by developing and disseminating quality standards and information for medicines, health care delivery, and related products and practices. Our standards and information help patients and practitioners maintain and improve health. 1 At the direction of its Board of Trustees, USP publishes USP -NF annually with 2 Supplements . These texts are continuously revised to account for new ingredients and products and for advances in analytical procedures. USP and NF are named as offi cial compendia in the FFDCA and are referenced in other laws and regulations, not only of the United States but of other countries as well.
USP is guided by resolutions adopted at the USP Convention, which meets every 5 years. Delegates to the March 2000 Convention endorsed 19 resolutions, one of which (Resolution 2) encouraged USP to perform the following:
Explore the feasibility and advisability of developing guidance on principles and approaches to assure equivalence of complex active ingredients (including botanicals and dietary supplements) recognizing the special issues associated with agents of biologic/biotechnological origin, including their regulatory control. 2 With encouragement and oversight from the Board of Trustees, USP formed an Expert Panel to consider this resolution.
DEFINITIONS
When a practitioner or consumer uses a drug, generally it is in a dosage form that contains a drug substance and one or more excipients. Drug substances may be categorized by type or source. By type, drug substances may be complex or noncomplex; by source, complex drug substances may be from natural sources (eg, plants and/or animals, including humans) or produced by recombinant DNA (rDNA) techniques -hence the terms biological and biotechnological drug substances and products. Below are a series of defi nitions of a biological substance.
World Health Organization
In the context of biological standardization, the World Health Organization (WHO) has defi ned a biological substance as " a substance which cannot be completely characterized by physicochemical means alone and which therefore requires the use of some form of bioassay. " 4 These assays involve comparison of the response of the test substance with that of a reference material. Since the 1920s, WHO has supplied international biological reference materials for such procedures.
United States Federal Food, Drug, and Cosmetic Act
Under the Act, biological and biotechnological medicinal products are considered drugs, and the term drug is defi ned as follows 5 :
articles recognized in the offi cial United States
Pharmacopoeia, offi cial Homeopathic Pharmacopoeia of the United States, or offi cial National Formulary, or any supplement to any of them; or 2. articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or other animals; or 3. articles (other than food) intended to affect the structure or any function of the body of humans or other animals; or 4 . articles intended for use as a component of any article specifi ed in clause (A), (B), or (C).
United States Public Health Service Act
A biological product subject to licensure under the United States Public Health Service Act (PHSA) is any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, applicable to the prevention, treatment, or cure of diseases or injuries to humans. 6 Biological products include, but are not limited to, bacterial and viral vaccines, human blood and plasma and their derivatives, and certain products produced by biotechnology, such as interferons and erythropoietins.
United Kingdom
The United Kingdom Biological Standards Act states that biologics are substances " whose purity or potency cannot be adequately tested by chemical or physical means. " 7 Other defi nitions of biologicals include the following:
• Products of living organisms used in the prevention or treatment of disease. 8 • A classifi cation of products derived from living sources, such as humans, animals, bacteria, and viruses. Vaccines, immune globulin, and antitoxin are biologics. 9 From the above, it is clear that consensus does not yet exist for a general defi nition of a biological or for ways to distinguish between complex and noncomplex active ingredients. However, as a general approach that forms the basis for the subsequent discussion (and recognizing many areas of overall agreement), a complex active ingredient may be viewed simply as one that (1) 
EQUIVALENCE CONCEPTS

Conditions When Similarity Questions Arise
Issues of similarity or lack thereof have been a theme of USP since its founding in 1820. In fact, the preface to the fi rst edition of USP in 1820 stated:
It is the object of a Pharmacopoeia to select from among substances which possess medicinal power, those, the utility E788 of which is most fully established and best understood; and to form from them preparations and compositions, in which their powers may be exerted to the greatest advantage. It should likewise distinguish those articles by convenient and defi nite names such as my prevent trouble or uncertainty in the intercourse of physicians and apothecaries. 10 Irrespective of proprietary naming considerations, therapeutic products that are therapeutically equivalent (ie, pharmaceutically equivalent and bioequivalent) should bear the same names; therapeutic products that are not should bear different names. Issues of equivalence arise continuously at various points in the life cycle of a manufactured drug substance and product. At least 3 can be clearly identifi ed. The fi rst is batch-to-batch equivalence when no change in method of manufacture or ingredients has occurred. This type of equivalence may be referred to as batch-to-batch consistency. The second is when a manufacturer makes one or more specifi ed changes to ingredients or method of manufacture. This type of equivalence is sometimes termed comparability. The third is when one manufacturer attempts to create a duplicate of another manufacturer ' s product, using different procedures, and at times different specifi cations. For a biological and biotechnological product, this type of equivalence is sometimes referred to as generic biologic, biogeneric, or follow-on biologic. The different terms used to express equivalence concepts -similar, same, identical, essentially similar, comparable, interchangeable, therapeutically equivalent, pharmaceutically equivalent, bioequivalent, follow-on biologic, and biogeneric -have varying scientifi c and legal meanings. 11 , 12 Depending on the degree of change, or, in the case of batch-to-batch consistency, when there is no deliberate change at all, the type and amount of data to demonstrate equivalence varies. This report focuses on general concepts and approaches to assess equivalence, irrespective of the specifi c setting in which the question arises. A risk management, assessment, and communications approach will help determine the number and types of tests that will be needed according to a specifi ed degree of change. This consideration is beyond the scope of this report but has been taken up by the United States Congress in the 1997 Food and Drug Administration Modernization Act (FDAMA), 13 in an International Conference on Harmonization (ICH) guideline, 14 in various FDA guidances, 15 , 16 and in other regulatory documents. 17 , 18 Equivalence Approaches: Hypothesis Testing
The scientifi c method begins with observation, which leads to a hypothesis (deductive reasoning). The hypothesis suggests an experimental study (inductive reasoning) that can refute or confi rm but can never unequivocally establish the hypothesis. Hypothesis testing usually begins with an assumption of no difference (the null hypothesis). If the experiment allows rejection of the null hypothesis, a difference may be concluded (the alternative hypothesis). In modern drug development, this approach is frequently used (eg, to test an active treatment compared with placebo). Equivalence testing is the reverse, where the null hypothesis is inequivalence and the alternative hypothesis is equivalence. 12 If the experiment allows rejection of the null hypothesis, equivalence is concluded. An equivalence approach uses a criterion, which forms the basis for the comparison, and equivalence limits (acceptance criteria), which are predetermined boundaries of in equivalence. These are nonstatistical judgments made by regulators, pharmacopeias, manufacturers, and others. Statistical tests are used to determine whether comparative data in an experimental population allow rejection of the null hypothesis of inequivalence and acceptance of the alternative hypothesis of equivalence. A standard approach 19 uses a confi dence interval (eg, 90%) to test equivalence; the observed interval (the 90% confi dence interval for the mean test and reference difference in the experimental population) must fall completely within predetermined acceptance criteria (eg, 80%-125%). Additional approaches that better account for variance also have been considered. 20
RESOLUTION 2
The 2000 USP Convention ' s Resolution 2 refers to complex active ingredients. These now include a broad range of ingredients and their corresponding dosage forms, including proteins, blood and blood products, vaccines, and celland gene-therapy products. The categories and classes within categories are expected to increase in the coming years, as therapeutic products from the molecular biology revolution increasingly become available. In considering Resolution 2, the Expert Panel agreed to focus on proteinbased complex active ingredients and their corresponding dosage forms, given that these now form the bulk of biological and biotechnological therapeutic products. They can be further classifi ed as peptides, nonglycosylated proteins, glycosylated proteins, and monoclonal antibodies ( Figure 1 ). Although Resolution 2 encouraged USP to also consider botanicals and dietary supplements, the Expert Panel did not include these types of ingredients and products in their deliberations. Many of the principles and approaches discussed for protein and other complex active ingredient drug products are, however, applicable to botanicals and dietary supplements.
EXPERT PANEL PRESENTATIONS AND DISCUSSION
Equivalence experiments can rely on a broad spectrum of marketplace surveillance, clinical benefi t, pharmacodynamic, pharmacokinetic, and nonclinical (animal) studies as well as physicochemical procedures. Depending on the
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procedures called for in an equivalence experiment, scientists must decide which measurements (end points) should be used for making comparisons. For clinical studies, these may be positive (eg, blood pressure lowering, rise in blood count, time to survival) or negative (eg, headache, fatigue) therapeutic outcomes. Special measurements, sometimes drawn from appropriate models, may be used for pharmacodynamic and pharmacokinetic studies. Physicochemical measurements include a broad array of approaches based on rapid advances in analytical procedures. Procedures can be used primarily for characterization or can become part of a specifi cation.
The selection of procedures to demonstrate equivalence will depend on the nature of the products, the private and/or public historical data already available, and the regulatory requirements. In process controls and end product specifi cations should be suitable to document batch-to-batch consistency. For intra-or intermanufacturer changes, a broad array of procedures may be required to demonstrate equivalence. 21 ; however, any opinions expressed here are solely those of the authors. These presentations were provided conceptually as a matrix, where the types of protein products were considered in terms of procedures that might be used to assess equivalence ( Tables 1 , 2 , 3 , 4 , and 5 ).
Matrix of Peptides and Proteins
Peptides
Peptides consist of generally between 10 and 40 amino acid residues. They are used in foods and in both human and animal health products. In human health products, they function as antibiotics, growth promoters, immunomodulators (both stimulants and suppressants), and agents to treat diabetes, pain, hypertension, and infertility. Examples include oxytocin, desmopressin, glucagons, secretin, calcitonins, leuprolide, somatostatin, and cyclosporine. Three major synthetic strategies for a peptide are (1) chemical (both solid-phase and solution-phase); (2) biochemical (eg, fermentation); and (3) rDNA technology. Chemical synthesis is by far the most common approach, with approximately half of manufacturers using solution-phase methods and half using solid-phase methods. Chemical synthesis must be controlled carefully to ensure completion of deprotection and coupling reactions, stability of side-chain blocking groups and peptide-resin bonding, and removal of 
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side-chain blocking groups. Because synthesis occurs through a series of steps, yield progressively decreases, with the increasing probability of truncated and internal deletion sequences. Common degradation products arising during synthesis include (1) asparagine deamidation, which generates aspartic acid and isoaspartic acid residues; (2) succinimide formation from aspartic acid, which is a precursor of isoaspartic acid; and (3) pyroglutamide formation from N-terminal glutaminyl peptides. Racemization is also a problem, which can be controlled and analyzed using various approaches. Biochemical synthesis may result in production of several species (eg, bacitracin), which can be acceptable in certain clinical settings. Stereospecifi city is a major advantage of biosynthesis. rDNA synthesis is generally used for larger peptides such as growth hormone and insulin. rDNA synthesis of peptides can rely on Escherichia coli , yeast, and mammalian host cells. This approach frequently results in a mixture of closely related species. Peptides produced in the host cell may not be stable, requiring fusion to a larger protein (eg, betagalactosidase) and subsequent cleavage. Translational fi delity with both mistranslation (occasional error in amino acid incorporation) and misincorporation (incorporation of wrong amino acid) can be a problem. Undesired posttranslational modifi cations may also occur. Various approaches to minimize these changes can be selected. Despite the small number of amino acid residues, peptides may have signifi cant structural characteristics, which presumably can affect clinical performance.
In contrast, because of the relatively small number of amino acid residues, peptides can be more thoroughly characterized than proteins. Purity of peptides may be determined by a variety of methods. Although physicochemical characterization and purity analyses are more straightforward than for proteins, these methods may still not be suffi cient to predict biologic toxicity and immunogenicity.
Nonglycosylated Proteins
Many of the issues associated with peptides are also common to nonglycosylated proteins, and additional issues arise as well. Variants of the desired molecule can be produced during synthesis, by chemical or physical reaction with manufacturing materials or components, or through degradation. For this reason, nonglycosylated proteins arising from rDNA synthesis tend to be heterogeneous. Additional complexity arises because of complex interactions of 
Continued
The AAPS Journal 2005; 7 (4) Article 77 (http://www.aapsj.org). 
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CE (free solution/gel fi lled) I/P X X <726> <1047> SDS-CE (free solution/gel fi lled) I/P X X <1047> HPLC (IEC, SEC, RP) I/P X X <621> Spectrophotometry/colorimetry I/P X X <851> Ligand binding assay Spectrophotometry/colorimetry I/P X X Fluorescence spectrophotometry I/P X X Fluorescence polarization measurements I/P X X SPR I/P X X Microarray (colorimetric, I/P X X spectrophotometric, radionucleotide, or fl uorescence detection) Competitive inhibition I/P X X NMR (T 1 or T 2 ) I X Equilibrium dialysis I X HP-SEC -column saturation technique I/P X Secondary structure CD I X X-ray diffraction I X Solution conformation CD I X Fluorescence spectrophotometry I X NMR (T 1 or T 2 ) I X
Continued
The AAPS Journal 2005; 7 (4) Article 77 (http://www.aapsj.org).
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proteins at receptor sites. For example, human growth hormone acts by binding to 2 different receptor binding sites (I and II) to produce a biologic response. Small changes arising in a natural-source or rDNA nonglycosylated protein may occur and may be diffi cult to detect as in the following examples: (1) in the deamidation of an amino acid; (2) when the substitution of one amino acid is not available in sufficient amounts during synthesis; (3) during acetylation, as acetate levels in the fermentation process rise; (4) during oxidation; (5) in the event of incorrect incorporation of amino acids when mammalian codons are used in bacterial plasmids; (6) during improper posttranslational folding, which is affected by disulfi de bonds; and (7) during carbamylation from process buffers such as urea, which may contain cyanate. Analytical procedures are increasingly powerful but still have limitations, including the following: (1) highperformance liquid chromatography (HPLC) may not detect an amino acid change " hidden " within the 3-dimensional structure of a protein; (2) mass spectrometry (MS) may require separation, affecting protein characteristics; (3) peptide maps may not always detect a change because of coelution; (4) pleiotropic proteins may require more than one bioassay (eg, growth hormone stimulates protein synthesis and lipolysis, inhibits insulin, stimulates new bone formation, and promotes erythropoiesis, with accelerated growth, reduction of adipose tissue, and increase in lean body mass); and (5) bioassays may not correlate well with human responses. For these reasons, analytical procedures alone, including bioassay, are limited in assessing the affect of change on the production of a nonglycosylated protein on clinical outcomes.
Glycosylated Proteins
Glycosylation is a posttranslation event that adds complex sugar (glycan) structures to specifi c amino acid sequences. With decreased glycosylation, binding to some receptors may be modulated. These effects can be manifested as changes in pharmacokinetics (eg, clearance), antigenicity, and activity. Despite its general importance, increased understanding of glycobiology indicates that glycosylation has varying degrees of effect. Glycosylation may directly affect activity, may indirectly affect activity (eg, through changes in pharmacokinetics), or may have no effect. Evaluation of this effect (and the effect of other posttranslational modifi cations) is thus an important part of any change control strategy. As with nonglycosylated proteins, full characterization of a glycosylated protein may not be possible, leading to a need for nonclinical and clinical studies to assess consistency in therapeutic outcomes in the presence of change. I/P X X Enzyme activity (see later)
The AAPS Journal 2005; 7 (4) Article 77 (http://www.aapsj.org). Testing can occur either with or without digestion (eg, papain digestion) to assess the activity of each of the domains individually. Oligosaccharide residues on a monoclonal antibody add complexity and require consideration because they can be involved in activity. Immunoglobulin structure and function are inherently complex. Immunoglobulin G and immunoglobulin M antibodies interact via numerous pathways with the immune system. Changes in the manufacturing process can involve both physicochemical characterization studies as well as assessment of change in response in biological systems (bioassays). As with nonglycosylated and glycosylated proteins, full character ization of a monoclonal antibody may not be possible, leading to a need for nonclinical and clinical studies to assess therapeutic outcomes in the presence of change.
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Procedures
Physicochemical Procedures
Natural-source and rDNA-derived peptides and proteins pose many analytical challenges arising from their complex structures, extent and nature of impurities (product, process, and contaminant impurities), pleiotropic biologic activities, and poor understanding of mechanism(s) of action. Typically, the numbers of assays that are performed for batch release are 3 to 4 times those used for a conventional small-molecule therapeutic. Impurities can include truncated forms, misincorporations, degradation products (eg, deamidated, oxidized, cleaved products), glycosylation errors, protein adducts, and host-cell contaminants (both proteins and DNA). Physicochemical measures may not correlate with enzyme-linked immunosorbent assays (ELISAs) or potency measurements because of variability and/or specifi city issues. Many proteins can bind to multiple receptors, and in vitro/in vivo correlations can be diffi cult to establish. Analytical procedures are developed in association with the capability/limitations of the process, with method validation conducted to demonstrate what is " known " about protein structure and function. Analytical procedures offer an increasingly broad array of techniques that are used for identity, quantifi cation, purity, structure, heterogeneity, activity, and stability studies. Despite a growing array of physicochemical information, variable effects in the clinic may still be observed in the presence of a manufacturing change. These effects sometimes occur in the absence of demonstrable physicochemical and biologic potency changes and sometimes do not occur even when signifi cant changes in these parameters can be demonstrated. Development of characterization I/P X X <727> <1047> SDS-CE (free solution/gel fi lled) I/P X X <1047> HPLC (IEC, SEC, RP) I/P X X <621> Spectrophotometry/colorimetry I/P X X <851> Assay activity (enzyme activity or Spectrophotometry/colorimetry I/P X X inhibition)
Fluorescence spectrophotometry I/P X X Fluorescence polarization I/P X X measurements SPR I/P X X Microarray (colorimetric, I/P X X spectrophotometric, radionucleotide, or fl uorescence detection) I X Crystal structure X-ray crystallography I/P X Molecular shape/ hydrodynamic volume Analytical ultracentrifugation I X Cell-surface or intercellular localization Electron microscopy I X Confocal microscopy I X Binding and intercellular transport Electron microscopy I X Video confocal microscopy I X Molecular topography Electron microscopy I X Atomic force microscopy I X *GC indicates USP General Chapter; PAGE, polyacrylamide gel electrophoresis; SDS, sodium dodecyl sulfate; IEF, isoelectric focusing; CE, capillary electrophoresis; CIEF, capillary isoelectric focusing; HP-IEC, high-performance liquid chromatography (HPLC) ion-exchange chromatography; RP-HPLC, reversed-phase HPLC; LC-MS, liquid chromatography-mass spectrometry; CE-MS, capillary electrophoresis-mass spectrometry; MALDI-TOF, matrix-assisted laser desorption/ionization-time of fl ight; NMR, nuclear magnetic resonance; HP-SEC, HPLC size-exclusion chromatography; MALLS, multiple angle laser light scattering detection; HPAEC-PAD, high pH anion-exchange chromatography with pulsed amperometric detection; PCR, polymerase chain reaction; SPR, surface plasmon resonance; and CD, circular dichroism. † I = Ingredient; P = Product. ‡ These tests are typically used as lot release tests; however, the actual lot release tests should be decided for individual intermediates (active ingredients) and products on a case-by-case basis based on characterization data, other pertinent information, and as needed to comply with regulatory requirements. Continued data versus mechanism of action may be used to develop a risk strategy in the presence of change for protein-based therapeutics, ranging from very low risk to high risk situations.
Continued
Biological Assays
A biologic assay is defi ned as an analytical procedure measuring a biological activity of a test substance based on a specifi c, functional, biological response of a test system. 22 , 23 Bioassays can rely on animals, in vitro cell lines, cell-based " biochemical " assays (kinase receptor activity, reporter genes), binding assays (immunoassays, biosensors), and enzyme assays. Bioassays are the only nonclinical tests that indicate a product is biologically active. They are informative in equivalence studies only to the extent that a change affects a part of the protein that affects activity. They can be limited in assessing the effect on some parameters (eg, pharmacokinetics) but critical in assessing immunogenicity. An immune response is assessed through measurement of antibody production. Only bioassays can confi rm if these antibodies neutralize biologic effect. Bioassays also are critical for structure/function studies. Although physicochemical procedures can detect the majority of modifi cations that occur with change, the effect of these changes can be as sessed only when the physicochemical change is correlated with biological activity. The 
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most well-characterized, precise bioassay is generally selected as the one for lot release potency. Care must be taken in this selection because of the pleiotropic activities of many proteins. When the mechanism of action is unknown or complex (eg, therapeutic vaccines), bioassays may be limited in value. Bioassays also are limited by a high degree of variability, which is generally higher for animal models, lower for cell-based bioassays or biochemical bioassays, and best with ligand binding/enzymes. Bioassays may not be needed for all peptide therapeutics but are of value for nonglycosylated and glycosylated proteins, particularly if they are stability indicating. They are also useful screening tools to assess relevance of changes in complex glycosylation patterns, particularly if they are in vivo based. Bioassays are also critical determinants of potency at the time of lot release and thus are of value even when no change occurs. The end result of this type of testing is a relative potency measure, expressed as units (or international units [IU])/mass of product. Potency is measured against international, USP, or in-house standards, or a predicate batch. This type of testing assesses batch-to-batch consistency against an equivalence interval of 100% of labeled claim. Bioassay testing for consistency, comparability, and equivalence relies on a determination of parallelism. Recent work at USP has suggested that improvements are needed in the statistical assessment of parallelism. 24 
Pharmacological and Toxicological Procedures
Experience during the past 2 decades has shown that the consequences of change in the manufacture of a naturalsource or rDNA protein are not always predictable using nonclinical studies. A key question thus arises: What effect will one or more changes that occur during the course of product development have on the product ' s safety and biologic activity? The signifi cance of a change can at times be assessed using assay/model systems that have been shown to be sensitive to a change. The types and timing of changes and the knowledge gained from past experience are thus inextricably linked to the design of pharmacology/toxicology studies to support an equivalence assessment. Current challenges in assessing equivalence of proteins include assay sensitivity and availability, lack of standards (positive and negative controls, reference standards), product availability from earlier processes for optimization of bridging studies, complications related to host-cell and processrelated impurities, and limitations of animal models in predicting human effects due to species specifi city.
Improved predictive value of preclinical safety studies has benefi ted from the ICH approaches and continues to improve with validation and acceptance of alternative methods, use of nontraditional animal models, technological advances, increasing reliance on surrogate and biomarkers, and other approaches. Comparison of conventional (small-molecule) therapeutics with natural-source and rDNA-derived protein therapeutics reveals both differences and similarities, some of which add additional study burden for second-entry interchangeable protein therapeutics, where issues of equivalence are involved. For example, many biological products are simple solution formulations given by injection that obviate the need to show bioequivalence. Because no drug or biological is 100% safe, the management of risks becomes a crucial factor in demonstrating equivalence. The use of appropriate animal models during development and manufacture of these products may provide supportive data for an equivalence determination, as it does now for conventional pharmaceuticals.
Pharmacokinetics
Pharmacokinetic studies are highly useful in assessing the impact of a change in the manufacture of a natural-source or rDNA-derived protein. An important feature of these studies is variability in absorption, distribution, and elimination. The sources of variability that can affect equivalence are intrinsic (physical and chemical properties, structural, genetic) or extrinsic (physiology, demographics, disease conditions). Although most proteins are administered by injection, absorption can vary depending on whether administration is subcutaneous, intramuscular, or intravenous. Formulation differences have also been shown to affect pharmacokinetics, even if the same route of administration is used. A variety of factors, including receptor density, physiological factors, glycosylation state, and physicochemical characteristics can affect distribution. Both oxidation and glycosylation are known to affect pharmacokinetics and, in certain settings, pharmacodynamics. Many investigations in both human and nonhuman species have shown that elimination is affected by protein molecular weight; examples exhibit many-fold differences in halflife. For proteins that are rapidly cleared by the liver, hepatic blood fl ow (which increases during exercise) can infl uence both the pharmacokinetics and pharmacologic effects. For these reasons, pharmacokinetics refl ective of tissue/organ distribution as well as systemic exposure measures, if relevant, may be useful in assessing equivalence. Pharmacokinetic studies for equivalence determinations on a solution of natural-source or rDNA-derived protein can be used to confi rm the identity of the active ingredient (ie, they are useful in establishing pharmaceutical equivalence). Design of a study will depend on the protein therapeutic, taking into account half-life, endogenous levels, need to study healthy versus patient volunteers, ethical considerations, and other factors. Standard approaches to equivalence now used in bioequivalence studies can be used to make comparisons.
Pharmacodynamics
Pharmacodynamic studies may be even more useful than pharmacokinetic studies, given that they more directly refl ect clinical outcomes and can change even when pharmacokinetic measures do not. Despite these advantages, pharmacodynamic studies also pose many challenges, including choice of study population, high inter-and intra-subject variability, change with disease progression, and diffi culty in interpretation because of pleiotropism, product-related substances, and process-and productrelated impurities. An example is intravenous immunoglobulin, which exhibits multiple mechanisms of action, multiple components in a preparation, and a high degree of inter-and intra-subject variability in clinical outcomes. Pharmacodynamic studies may not always allow focus on the ultimate clinical benefi t because of disease progression, study duration, ethical issues, and other factors. Instead, pharmacodynamic studies usually focus on a surrogate or biomarker of interest that waxes and wanes over a time period that allows adequate study. Pharmacodynamic studies allow comparisons between pre-and postchange dosage forms, by facilitating comparison of a suitable surrogate or biomarker (eg, platelet aggregation following administration of antiplatelet therapy in the treatment of myocardial infarction). Direct comparisons rely on measures similar to those for pharmacokinetic studies (eg, area under the effect curve/AUEC and peak effect/Cpeak). More complex pharmacokinetic and pharmacodynamic modeling may also provide better mechanistic understanding, verify kinetic equivalence, and allow discrimination of " system " versus product variability. The benefi t may also be limited because of high variability, low precision and accuracy, and ethical diffi culty in approaching maximal effect. Because maximal effect is related to receptor number, it can refl ect changes more of the in vivo system itself rather than the protein under investigation. Because the focus of a pharmacodynamic study is on a specifi c end point related to the naturalsource or rDNA biologic, a case-by-case approach is generally needed.
Clinical Effi cacy and Safety
Clinical studies may be used to assess equivalence using both safety and effi cacy end points. They are used in this context now to show equivalence for some conventional pharmaceuticals where reliance on systemic exposure measures is not suitable. Noninferiority studies have been considered in detail in the ICH E10 guidance. 25 According to the E10 approach, a new drug or regimen may have benefi ts with respect to a primary or secondary end point in comparison to the existing drug or regimen. In such cases, it is not necessary for the new regimen to be superior to the existing regimen with respect to all the end points. For example, if survival is the primary end point, the new regimen with an improved safety profi le need only be similar with respect to survival in order to be the preferred regimen. The noninferiority term captures the one-sidedness of the primary hypothesis (eg, the product after a change can be better for some end points but should remain within a specifi ed lower bound margin for others). The approach is applicable to equivalence testing for a natural-source or rDNA-derived protein, where both noninferiority and nonsuperiority would be assessed. With this approach, relevant clinical outcomes should stay within both upper and lower bounds, which is the equivalence interval.
Immunogenicity
Serious adverse events (eg, pure red cell aplasia) have raised concerns about postapproval change both within and between manufacturers of natural-source and rDNAderived proteins. 
THE ROLE OF THE UNITED STATES PHARMACOPEIA
Monographs
A public monograph in USP -NF helps practitioners and other interested parties understand how an article ' s strength, quality, and purity should be controlled. Various terms are used to express the overall quality of a therapeutic article -ICH: quality; FFDCA: identity, strength, quality, purity, and potency; and PHSA: safety, purity, and potency. By the use of appropriate naming conventions, they support " clear, useful " names that help practitioners intelligently and safely use a therapeutic product. The case for a public monograph to support equivalence testing can also be made. WHO and various regulatory agencies subdivide equivalence approaches into (1) pharmaceutical equivalence (same active ingredient, same dosage form, same route of administration, and the same strength or concentration), and (2) bioequivalence (same rate and extent of availability after administration at the same concentration). For solid dosage forms containing noncomplex (pharmaceutical) drug substances, equivalence experiments focus on bioequivalence, given that documentation of pharmaceutical equivalence for a well-characterized active ingredient is relatively easy. In this context, a modern USP monograph is at least a start -and sometimes more than a start -in determining pharmaceutical equivalence. For a dosage form containing a biological or biotechnological drug substance, the emphasis is on pharmaceutical equivalence, because dosage forms of these substances are mostly parenteral solutions. Bioequivalence, which focuses on comparative release of the drug substance from test and reference dosage forms, is considered self-evident for parenteral solutions. Pharmaceutical equivalence experiments of 2 dosage forms containing a noncomplex active ingredient focus on the active ingredient itself, given that the remaining elements of pharmaceutical equivalence are generally satisfi ed without debate. At 21 Code of Federal Regulations ( CFR ) 320.22(b)(1)(ii) excipients for a parenteral dosage form submitted pursuant to 505( j) must be qualitatively and quantitatively identical to the reference listed drug. This may not be possible for interchangeable generics containing complex active ingredients. Again, for a complex active ingredient, a USP monograph is a start, and sometimes more than a start, in determining pharmaceutical equivalence for natural-source or recombinant complex active ingredients. It creates a foundation to which all manufactured ingredient and product articles should conform.
Despite the value of a general public standard, the monographs for a biological and/or biotechnological drug substance and dosage form should be fl exible to account for different impurities, especially when the manufacturing processes are different. This also is true of noncomplex active ingredients and products. Unlike other pharmacopeias, USP generally does not provide process information in a monograph, except to the extent that it defi nes an article as synthetic, natural, or biotechnological. Thus, a USP monograph is a starting point for subsequent-entry manufacturers, recognizing that substantial additional one-time characterization studies may be needed to document equivalence. Review of these studies is the province of the regulatory agency.
At this time, public monographs in USP are available for only a few rDNA-derived protein-based therapeutics. They also are not available in CFR . This differs from the approach used for antibiotics, which historically parallels in some ways the evolution of control for rDNA-based therapeutics. In the case of antibiotics, the United States initially required extensive governmental lot release testing without reliance on USP monographs and offi cial USP Reference Standards. To satisfy the need for public monographs, the government published antibiotic monographs in CFR . With advances in analytical procedures and manufacturing capability, the United States government abandoned antibiotic lot release testing and, with deletion of Section 507 of FFDCA in the 1997 FDAMA, terminated CFR publication of public antibiotic monographs. Since then USP has developed full monographs for antibiotics, working collaboratively with FDA. USP has worked collaboratively with FDA on antibiotic reference standards since the 1970s, when the FDA antibiotic reference standard program was transferred to USP. In contrast, FDA has not promulgated public monographs for natural-source or rDNA-derived proteins, either in CFR or by working collaboratively with USP. There are also few public standards for these articles and little or no public collaborative testing of them.
General Chapters
In assessing equivalence between 2 complex actives-based dosage forms, a key question is how much additional characterization data are needed beyond the tests in a USP -NF monograph. USP is working to make its monographs more complete and fl exible in order to account for different routes of synthesis and different impurity profi les. Nonetheless, the additional studies needed to confi rm equivalence for 2 biologicals drawn from different sources may require comparative clinical, pharmacodynamic, pharmacokinetic, and other nonclinical studies. These one-time characterization studies are beyond the scope both of a private standard and standards in a public pharmacopeial monograph. Nonetheless, in General Chapters, USP can create useful techniques that form the basis for private characterization studies that support both public and private standards. To the extent that these can be prospectively harmonized they are even more valuable. Maps of USP -NF General Chapters useful to manufacturers of protein-based therapeutics are shown in Figures 2 and 3 .
Reference Standards
Offi cial USP Reference Standards, generally referenced in monographs or in General Chapters, are highly purifi ed physical materials that are approved by the USP Reference Standards Committee. There are 6 different types of reference standards, and each can play an important role in equivalence studies.
Drug Substance Reference Standards
These are the traditional USP reference standards, used in important tests of a monograph. In general, they are articles of commerce donated to USP. In USP laboratories, they undergo careful recharacterization testing and collaborative studies to 
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assess content. By comparison with noncomplex products, collaborative studies for natural-source and rDNA-derived protein therapeutics involve more laboratories because of the variability of the assays, especially bioassays in animals or cell-based tests. Potency in USP units is assigned to the reference standard based on these collaborative studies.
Drug Product Reference Standards
In general, a drug substance reference standard is also used for procedures that assess the drug product. By its very nature, the manufacture of complex active products sometimes bypasses the drug substance stage and goes directly to either a concentrate or a fi nished product. Because equivalent products do not always have to have identical excipients, the presence of different excipients in each of the products may interfere with the tests and assays. This issue requires resolution by a manufacturer working with USP to ensure compliance with the compendial monograph.
Impurities Reference Standards
Equivalence studies involving 2 complex products that are produced using different routes (eg, yeasts, E coli , animal, 
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or human cells) should take into consideration the impurity profi les of each of the resulting products. Because of the different vectors, the fi nal impurity profi les will have, in all likelihood, similar or different impurities at different levels. Because impurity profi les are a factor in the safety and effi cacy of products, their determination and quantitation will require the use of more than one impurity reference standard.
Procedural Reference Standards
This reference standard may be used by analysts during procedure development and validation, as well as in routine tests to ensure that the procedure, under the conditions of use, is working as intended and as validated. It is generally recognized that bioassays are highly variable. In equivalence studies, especially for complex active substances and products, the relative lack of accuracy and precision can bias an equivalence determination. A procedural reference standard will standardize the procedure used regardless of the product, thus reducing the uncertainty of the results. Procedural reference standards are being developed for methods used to characterize complex actives products (eg, amino acid analysis).
Ancillary Materials Reference Standards
Ancillary materials are chemical or biological substances used during the manufacture of complex actives products and are not intended to remain in the final product. The quality and the performance of these materials are part of the overall quality requirements of the finished product in order to ensure consistency among batches of final products. Furthermore, residues of these ancillary materials should not be present in the final products. Standardization of the ancillary materials requires the use of reference standards for comparison purposes. Equivalence studies of products with different ancillary material profiles will require testing of the final products for different residuals, depending on the manufacturing process.
Reagents Reference Standards
The reliability of noncompendial and compendial tests and assays -once the drug substance reference standards, the procedures used via procedural reference standards, and the ancillary materials have been standardized -depends on the quality of the reagents used in these assays and tests. Variability in tests and assays can be introduced by variability of reagents, which of course will bias the results as attempts are made to determine the equivalence of products.
USP is developing reagents reference standards for complex actives.
SUMMARY
This report summarizes USP perspectives on equivalence approaches for complex active ingredients and dosage forms. The report focuses on protein-based therapeutics, with the understanding that approaches and principles for these articles may be generally applicable to other biological and biotechnological products. The primary responsibility for documenting equivalence rests with pharmaceutical manufacturers. Given various safety and other considerations, these data will usually require regulatory review. In this regard, regulatory agencies can assist manufacturers by delineating in regulation or guidance the type and amount of data needed depending on the type of change. Depending on the article and its safety and effi cacy profi les, this information will need to be determined case by case. Public or private prior knowledge will assist manufacturers in making changes -without reliance on this prior knowledge, a full complement of safety and effi cacy studies would be needed to justify even minor changes. Regulatory judgments based on prior experience are critical, given that requirements can be made so stringent that no manufacturing change would be allowed. The argument that manufacturers should develop optimal information about their processes and how they infl uence the strength, quality, and purity and also safety and effi cacy of a manufactured article applies to all manufacturers. 26 It is not suffi cient, however, to say that the required information to support a change can reside only with one manufacturer. Rather, any manufacturer of a natural-source or rDNA-derived protein therapeutic should conduct the characterization studies to support the necessary specifi cations for ingredients and fi nal products. 27 , 28 The specifi cations may be used to allow batch release and assess batch-to-batch consistency. The information to document comparability and/or equivalence in the presence of change is a separate set of information, as discussed in this article. USP can provide public monographs that provide a baseline set of quality requirements for all manufacturers. In addition, USP can provide offi cial USP Reference Standards for articles, impurities, procedures, ancillary materials, and reagents. Taken together, the various manufacturer, regulatory, and compendial risk-based approaches can assure the public that complex active ingredients and their dosage forms will be safe, effective, and equivalent from batch to batch and in the presence of intra-and intermanufacturer changes in components and composition and method of manufacture.
